Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yili L Pritchett

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Biopharmaceutical Statistics|February 26, 2010
Baseline observation carry forward: reasoning, properties, and practical issuesJun Shao, David C Jordan, Yili L Pritchett
Journal of Biopharmaceutical Statistics|November 30, 2019
ASIED: a Bayesian adaptive subgroup-identification enrichment designYanxun Xu, Florica Constantine, Yuan Yuan, et al.
International Clinical Psychopharmacology|October 3, 2006
Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?David G S Perahia, Yili L Pritchett, Durisala Desaiah, et al.
The Journal of Pain|August 12, 2009
The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disordersJohn T Farrar, Yili L Pritchett, Michael Robinson, et al.
Pain Medicine (Malden, Mass.)|July 31, 2007
Duloxetine for the management of diabetic peripheral neuropathic pain: response profileYili L Pritchett, Bill H McCarberg, John G Watkin, et al.
International Clinical Psychopharmacology|April 15, 2008
Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetineMadhukar H Trivedi, Durisala Desaiah, Melissa J Ossanna, et al.
Journal of Psychiatric Research|August 29, 2006
Use of effect size to determine optimal dose of duloxetine in major depressive disorderYili L Pritchett, Martin D Marciniak, Patricia K Corey-Lisle, et al.
Diabetes Care|March 1, 2007
Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic painDan Ziegler, Yili L Pritchett, Fujun Wang, et al.
Pain Medicine (Malden, Mass.)|November 4, 2005
A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic painJoel Raskin, Yili L Pritchett, Fujun Wang, et al.
Current Therapeutic Research, Clinical and Experimental|March 29, 2014
Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trialJoachim F Wernicke, Joel Raskin, Amy Rosen, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Biopharmaceutical Statistics|February 26, 2010
Baseline observation carry forward: reasoning, properties, and practical issuesJun Shao, David C Jordan, Yili L Pritchett
Journal of Biopharmaceutical Statistics|November 30, 2019
ASIED: a Bayesian adaptive subgroup-identification enrichment designYanxun Xu, Florica Constantine, Yuan Yuan, et al.
International Clinical Psychopharmacology|October 3, 2006
Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?David G S Perahia, Yili L Pritchett, Durisala Desaiah, et al.
The Journal of Pain|August 12, 2009
The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disordersJohn T Farrar, Yili L Pritchett, Michael Robinson, et al.
Pain Medicine (Malden, Mass.)|July 31, 2007
Duloxetine for the management of diabetic peripheral neuropathic pain: response profileYili L Pritchett, Bill H McCarberg, John G Watkin, et al.
International Clinical Psychopharmacology|April 15, 2008
Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetineMadhukar H Trivedi, Durisala Desaiah, Melissa J Ossanna, et al.
Journal of Psychiatric Research|August 29, 2006
Use of effect size to determine optimal dose of duloxetine in major depressive disorderYili L Pritchett, Martin D Marciniak, Patricia K Corey-Lisle, et al.
Diabetes Care|March 1, 2007
Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic painDan Ziegler, Yili L Pritchett, Fujun Wang, et al.
Pain Medicine (Malden, Mass.)|November 4, 2005
A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic painJoel Raskin, Yili L Pritchett, Fujun Wang, et al.
Current Therapeutic Research, Clinical and Experimental|March 29, 2014
Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trialJoachim F Wernicke, Joel Raskin, Amy Rosen, et al.
Pageof 2